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ABSTRACT
Coformulations are a novel pharmaceutical
development in diabetology. They are
composed of two medicinal products, both of
which maintain their distinct pharmacokinetic
and pharmacodynamic properties. Currently
available coformulations include combinations
of basal and rapid-acting insulin, and basal and
glucagon-like peptide 1 receptor agonists
(GLP1RA). This review describes three
coformulations which are in advanced stages
of development, or are approved in certain
markets. We discuss the basic and clinical
pharmacology of these drugs, while describing
clinical usage of the commercially available
insulin degludec aspart (IDegAsp).
Keywords: BEGIN; BOOST; DUAL; GetGoal;
Insulin degludec aspart; Insulin degludec
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COFORMULATIONS
IN DIABETOLOGY
Fixed dose combination (FDCs) and fixed ratio
combinations (FRCs) or fixed proportion
combination (FPCs) are an integral and well-
accepted part of diabetes care. Oral FDCs are
convenient to use and well tolerated in patients,
and their efficacy has been well demonstrated
[1]. Injectable FRCs or FPCs, such as pre-mixed
insulin, are also widely used in diabetes
management [1]. These FRCs provide
convenient, effective and safe glycemic
control. However, the traditionally available
FRCs are mixtures of two components which
merge with each other in the solution, and may
lose their distinct pharmacokinetic and
pharmacodynamic profiles [1]. This may lead
to limitations in onset of peak or duration of
action, and may result in suboptimal efficacy.
Recently, injectable coformulations have been
developed, which combine two distinct
molecules in one formulation. These may be
Electronic supplementary material The online
version of this article (doi:10.1007/s13300-015-0106-2)
contains supplementary material, which is available to
authorized users.
S. Kalra (&)




Government Medical College and Hospital,
Chandigarh, India
Diabetes Ther (2015) 6:101–111
DOI 10.1007/s13300-015-0106-2
from the same therapeutic class (e.g., a rapid
acting insulin combined with a basal insulin) or
from different therapeutic classes (e.g., a basal
insulin combined with a glucagon-like peptide
1 receptor agonist [GLP1RA]).
The dictionary defines ‘‘formulation’’ as ‘‘the
act, process or result of formulating or
reducing to a formula’’ or ‘‘a medicinal
preparation’’, and defines coformulation as
‘‘the act of packaging more than one drug
into one pill’’ [2]. It must be noted that no
injectable coformulations have been described
as such until now. The word ‘‘injection’’ when
used in terms of drug dosage refers to solution,
suspension and emulsion, including those
produced from powders or concentrated
solutions. Various oral coformulations such as
multivitamins, vitamin B complex and certain
antibiotics (e.g., co-amoxiclav) are available for
intravenous use. Such pharmaceutical
advances, however, have not been available
in the anti-diabetic segment so far. This is
because the challenges of producing and
combining biologically engineered molecules,
such as insulin and GLP1RA, are infinitely
greater than those utilizing synthetic chemical
compounds.
In this review, we define injectable
pharmaceutical coformulations as
preparations, and which also maintain their
distinct pharmacological properties. These are
distinct from the pre-mixed insulins that have
been available over the last 50 years (Table 1).
CLASSIFICATION
In this review, we discuss the following
coformulations, which are based on insulin as
a common compound. These coformulations
may or may not include a GLP1RA.
1. Ultra-long-acting insulin ? rapid-acting
insulin:
(a) Insulin degludec aspart (IDegAsp)
2. Insulin ? GLP1RA:
Table 1 Coformulation versus pre-mixed preparation
Characteristic Coformulation Pre-mixed preparation
Deﬁnition Formulation of two separate components, which maintain
distinct identity
Mixture of two components, which






Both components maintain distinct PK/PD proﬁles PK/PD proﬁle of both components
may merge
Efﬁcacy Both components achieve efﬁcacy at targeted endpoint Both components often achieve
targeted end points
Scope Allows coformulation of separate classes of drugs Does not allow mixing of different
classes of drugs
Examples Insulin degludec ? insulin aspart; insulin
degludec ? liraglutide; insulin glargine ? lixisenatide
Biphasic human insulin; biphasic
insulin aspart; biphasic insulin
lispro
PD pharmacodynamics, PK pharmacokinetics
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(a) Insulin degludec liraglutide (IDegLira)
(b) Insulin glargine lixisenatide (IGlarLixi)
INSULIN DEGLUDEC AND INSULIN
ASPART
Insulin degludec and insulin aspart (IDegAsp) is
a novel, soluble coformulation comprising
insulin degludec, an ultra-long-acting basal
insulin analog, and insulin aspart, a rapid-
acting insulin analog. This coformulation is
made up of 70% insulin degludec and 30%
insulin aspart.
Insulin degludec forms a soluble and stable
dihexamer, using phenol and zinc. While zinc is
responsible for the formation of hexamers,
phenol maintains the molecule in a
dihexameric form so that the multihexamers
are not formed in the solution. Following
injection into the subcutaneous tissue, phenol
diffuses away from the formulation leading to
the formation of multihexamer chains, which
act by causing a slow, continuous and extended
release of monomers from the injection site [3].
Insulin degludec has a very long duration of
action ([42 h) with four times lower glycemic
variability than insulin glargine at steady-state
concentration [3]; this translates into a much
lower risk of hypoglycemia, especially




These two insulin analogs have been
coformulated in such a manner that they
neither interfere with the pharmacokinetics of
each other nor cause any change in the mode of
action of each other [5]. Receptor affinities of
various newer insulins have always been a cause
of concern, especially insulin-like growth factor
1 (IGF-1) receptor binding affinity, which could
induce mitogenesis and carcinogenicity when
at high levels. These properties of insulin
degludec [6] and insulin aspart [7] were
respectively investigated in vitro, as briefly
mentioned in Table 2.
Clinical Trial Program
The efficacy and safety of IDegAsp has been
studied in the phase 3 BOOST clinical trial
program. These clinical studies were conducted
in patients with both type 1 diabetes mellitus
(T1DM) and type 2 diabetes mellitus (T2DM),
both as once-daily (OD) and twice-daily (BID)
dosing. The endpoints of this trial are
summarized in Table 3.
Regulatory Approval Status
IDegAsp has recently received market approval in
the European Union, Japan, Mexico, India and
Bangladesh for the treatment of T1DMandT2DM.
Posology
As per the IDegAsp label, IDegAsp can be
administered OD or BID with main meal(s). In
Table 2 Receptor binding and metabolic and mitogenic










IGF receptor afﬁnity 100% 2% 81%
Metabolic potency 100% 8–20% 101%
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patients with T2DM, IDegAsp can be
administered either alone or with oral anti-
diabetic medicinal products and in
combination with bolus insulin. In patients
with T1DM, IDegAsp is used in combination
with short-/rapid-acting insulin with remaining
meals. Dose adjustments are recommended to
be primarily assessed based on fasting plasma
glucose measurements. Flexibility in dosing
time of IDegAsp allows for flexibility in the
timing of insulin administration, as long as it is
administered with main meal(s). If a dose of
IDegAsp is missed, patients should not take an
extra dose to make up for a missed dose, but can
take the missed dose with the next main meal of
that day and then resume the usual dosing
schedule the following day.
The recommended total daily starting dose
for patients with T2DM is 10 unit with the main
meal(s), followed by individual dosage
adjustments. The recommended starting dose
of IDegAsp in patients with T1DM is 60–70% of
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T2DM: IDegAsp BID versus
BB regimen with OD IDeg
















BB basal bolus, BiAsp biphasic insulin aspart 30/70, BID twice daily, ETD estimated treatment difference, FPG fasting
plasma glucose, HbA1C glycated hemoglobin, IAsp insulin aspart, IDeg insulin degludec, IDegAsp insulin degludec aspart, ns
not signiﬁcant, IDet Insulin detemir, IGlar insulin glargine, OD once daily, T1DM type 1 diabetes mellitus, T2DM type 2
diabetes mellitus
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the total daily insulin requirements with short-/
rapid-acting insulin at the remaining meals,
followed by individual dosage adjustments.
Patients with T2DM switching from once-
daily basal or pre-mixed insulin therapy can be
given unit-to-unit, once-daily IDegAsp at the
same total insulin dose as the patient’s previous
total daily insulin dose. Patients switching from
more than once-daily basal or pre-mixed insulin
therapy can be converted to unit-to-unit, twice-
daily IDegAsp at the same total insulin dose as
the patient’s previous total daily insulin dose.
Patients switching from basal/bolus insulin
therapy to IDegAsp will need to convert their
dose based on individual needs. In general,
patients are initiated on the same number of
basal units.
Special Populations
IDegAsp can be used in elderly patients (aged
[65 years) and in renal and hepatic impaired
patients with intensified glucose monitoring
[8]. The insulin dose should be adjusted on an
individual basis. The safety and efficacy of
IDegAsp in children and adolescents aged
under 18 years have not been established, and
so this coformulation is not currently approved
for use in children.
INSULIN DEGLUDEC
AND LIRAGLUTIDE
Insulin degludec and insulin liraglutide
(IDegLira) is a fixed-dose, once-daily
combination of ultra-long-acting insulin
degludec and liraglutide, a GLP1RA. It has been
developed for use in patients with T2DM and can
be given in a single, daily subcutaneous injection.
The use of insulin is often associated with
hypoglycemia and weight gain, hence delaying
the initiation and intensification of the insulin
regimen [14]. When used alongside insulin,
GLP1RAs can play an important complimentary
role, as their use has been associated with a lower
incidence of hypoglycemia and weight loss; this
could be due to loss of appetite, as is often seen
with the use of GLP1RA [14]. Therefore, when
administered together, this combination can be
very successful in themanagement of T2DM. The
combined use of basal insulin and GLP1RA
analogs has also been jointly recommended by
the American Diabetes Association (ADA) and
European Association for the Study of Diabetes
(EASD) [14].
Rationale
Many studies combining basal insulin analogs
with GLP1RA have shown synergistic beneficial
effects of these therapies with better safety
profiles.
In a 26-week randomized, open-label study
of patients with poorly controlled T2DM,
addition of liraglutide to metformin treatment
followed by intensification with basal insulin
(insulin detemir [IDet]) showed that 61% of
participants completing the run-in achieved
glycated hemoglobin (HbA1C) levels of \7%
(mean change -1.3%) compared with
liraglutide alone [15]. At 26 weeks, HbA1C
further decreased by 0.5% with IDet versus a
0.02% increase without IDet (estimated
treatment difference -0.52; 95% confidence
interval [CI] -0.68 to -0.36; p\0.0001). At
week 26, HbA1C levels of\7% were achieved in
43% of patients taking IDet versus 17% patients
not taking IDet. Sustained weight loss was
observed during the study; however, there
were higher rates of minor hypoglycemia in
patients treated with IDet compared to without
IDet (9.2 versus 1.3%, p = 0.004) [15].
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The efficacy and safety of adding long-acting
GLP1RA liraglutide OD versus adding short-
acting insulin aspart (IAsp) OD to long-acting
insulin degludec (IDeg) OD ?metformin in
subjects with T2DM was first investigated in
the BEGIN: VICTOZA ADD-ON trial [16].
Eligible subjects completing 104 weeks of
treatment with IDeg ?metformin in preceding
trials were randomized to intensify treatment
by adding either liraglutide or IAsp OD, on top
of IDeg ?metformin if their HbA1C was C7%
(C53 mmol/mol). After 104 weeks, a third arm
was included to evaluate the durability of IDeg
to maintain glycemic control over an additional
26 weeks comprising non-randomized subjects
with HbA1C of\7.0%. The results showed that
IDegLira reduced HbA1C (-0.74% points)
significantly more than IDegAsp (-0.39%
points; p = 0.0024). 49.4% of subjects in the
IDegLira arm and only 7.2% in the IDegAsp arm
achieved HbA1C of \7% without confirmed
hypoglycemia or severe hypoglycemia, and
without weight gain (p\0.0001). IDegLira
subjects had significantly less confirmed and
nocturnal confirmed hypoglycemia, and
significantly greater weight loss (-2.8 kg)
versus IDegAsp (?0.9 kg; p\0.0001) [16].
Pharmacokinetics
and Pharmacodynamics
IDeg is a basal insulin with an ultra-long
duration of action that forms soluble multi-
hexamers at the injection site following
subcutaneous administration and a half-life of
24 h [17]. Liraglutide is a human GLP1RA with
97% homology. The peptide precursor of
liraglutide is produced using recombinant
DNA technology in yeast (Saccharomyces
cerevisiae). In a dose escalation study in
healthy subjects, five consecutive dose levels
(1.25, 5.0, 7.5, 10.0 and 12.5 lg/kg) of
liraglutide were given subcutaneously on day 1
and days 5 to 11. A steady state was observed
after three doses and the half-life was
determined to be 12.6 ± 1.1 h [18].
Phase 3 Clinical Trial Program
The DUal Action of Liraglutide and Insulin
Degludec in Type 2 Diabetes (DUAL) trial
includes two phase 3a trials encompassing
around 2000 people with T2DM. It was
designed to study the efficacy and safety of
combined use of insulin degludec and
liraglutide. All treatments in both the trials
were given subcutaneously and could be given
at any time of day, provided the chosen time
was used consistently every day.
The main features and the study results of
both the DUAL programs (I and II) are shown in
Table 4.
Regulatory Approval Status
IDegLira has been given market authorization
by the European Medical Agency (EMA), which
is valid throughout the EU [21].
INSULIN GLARGINE
AND LIXISENATIDE
Lixisenatide is a new selective once-daily
GLP1RA in development for the treatment of
T2DM [22]. In a 13-week, phase II study, the
optimal dose of lixisenatide was found to be
20 lgOD.At this dose, significant improvements
in HbA1C versus placebo were observed, with a
good efficacy/tolerability ratio [22]. Lixisenatide
has demonstrated dose-dependent
improvements in post-meal glucose levels and
suppression of postprandial glucagon secretion
in patients with T2DM insufficiently controlled
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with metformin, as well as pharmacodynamic
effects consistent with a glucose-dependent
effect on insulin secretion and suggested
improvements in b-cell function [23].
Clinical Trial Program
A phase 3 clinical trial program named GetGoal,
which included 10 clinical trials, has been
carried out to establish the safety and efficacy
of insulin glargine and lixisenatide
combination for the management of patients
of T2DM. Table 5 summaries a few important
trials of GetGoal program.
CONCLUSION
IDegAsp is the first soluble coformulation with
both the basal and bolus insulin components
available with the pharmacokinetic profile well
retained unlike the previously available
biphasic insulin preparations. Also, no re-
suspension is required before using IDegAsp,
unlike other biphasic insulin preparations. This
coformulation has shown non-inferiority in
HbA1C control in comparison to the currently
available basal and pre-mixed insulins both as
OD dosing and BID dosing with lower risk of
hypoglycemia. It is anticipated to offer clinical
advantage over currently available pre-mixed
insulin suspensions.
GLP1RAs have been designed to restore and
maintain incretin glucagon-like peptide 1 levels
and attenuate postprandial plasma glucose
excursions. Currently, four GLP1RAs are
available for the treatment of T2DM: exenatide
BID; a long-acting formulation, once weekly;
liraglutide OD; and prandial lixisenatide OD.
Table 4 DUAL I and DUAL II clinical trial program
Population Number
of weeks
Non-inferior HbA1C Other important points regarding
conﬁrmed hypoglycemia and
weight change
DUAL I: T2DM: IDegLira
OD versus insulin degludec
OD versus liraglutide OD
(n = 1663) [19]
26 Mean HbA1C decreased by 1.9%
with IDegLira, by 1.4% with insulin
degludec, and by 1.3% with
liraglutide. IDegLira was non-
inferior to insulin degludec
(p\0.0001) and superior to
liraglutide, (p\0.0001)
36% Of patients on IDegLira, 14% of
patients on insulin degludec and
52% of patients on liraglutide
achieved HbA1C levels of\7%
without any weight gain and
hypoglycemia
Number of conﬁrmed hypoglycemic
events per patient year was 1.8 for
IDegLira, 2.6 for insulin degludec
and 0.2 for liraglutide
DUAL II: T2DM: IDegLira
OD ? metformin versus
IDeg OD ? metformin
(n = 413) [20]
26 Superior HbA1C reduction with
IDegLira by 1.9% versus 0.9% by
insulin degludec (p\0.0001)
Mean weight change of 2.7 kg with
IDegLira versus no weight change
with insulin degludec, (p\0.0001)
Comparable incidence of conﬁrmed
hypoglycemia was seen in 24% of
patients on IDegLira versus 25% of
patients on insulin degludec
HbA1C glycated hemoglobin, IDegLira insulin degludec liraglutide, OD once daily
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Table 5 GetGoal clinical trial program
Study design (n) Weeks Non-inferior HbA1C Other important points regarding
conﬁrmed hypoglycemia and
weight change
GetGoal Duo 1 [24]: double-blind,
parallel group trial in which
patients not achieving target
HbA1C of\7% with insulin
glargine were given lixisenatide or
placebo as add on therapy (446)
24 Adding lixisenatide to insulin
glargine further reduced HbA1C
by 0.71% versus 0.40% with
placebo (p\0.0001)
More participants attained HbA1C
7% with lixisenatide (56% versus
39%; p\0.0001)
Lixisenatide reduced 2 h PPG more
than placebo (p\0.0001)
Lixisenatide had a favorable effect
on body weight (-0.89 kg
compared to placebo; p = 0.0012)
Nausea, vomiting, and symptomatic
hypoglycemia (3.3 mmol/L) were
more common with lixisenatide
GetGoal-M [25]: double-blind
placebo-controlled study where the
patients were randomized to
receive injections of lixisenatide in
the morning, lixisenatide in the
evening, placebo in the morning,
or placebo in the evening (680)
24 From a baseline HbA1C of 8.1%,
administration of lixisenatide led
to a decrease of -0.9% (morning
injection) and -0.8% (evening
injection) versus -0.4% with
placebo (primary end point) at
24 weeks
Mild and transient nausea and
vomiting were the most commonly
reported and only notable
treatment emergent adverse events
Hypoglycemia frequency was slightly
higher in the lixisenatide groups
versus placebo, but remained low
with no cases of severe
hypoglycemia
GetGoal-L [26]: efﬁcacy and safety
of lixisenatide as an add-on
therapy to basal insulin was
investigated in patients
inadequately controlled on a
combination of basal
insulin ± metformin (495)
24 Lixisenatide signiﬁcantly reduced
HbA1C by -0.7 ± 0.1% versus
-0.4 ± 0.1% with placebo at
24 weeks (p = 0.0002) and
increased the proportion of
patients achieving HbA1C\7%
(28.0% versus 12.0% for placebo;
p\0.0001)
Lixisenatide reduced body weight
compared with placebo
(p\0.0001). A decrease in insulin
dose at study end was seen with
lixisenatide compared with placebo
(-5.6 versus -1.9 U; p = 0.012)
Incidence of symptomatic
hypoglycemia was comparable
(27.7% for lixisenatide versus
21.6% for placebo), whereas four
cases of severe hypoglycemia
occurred in the lixisenatide group
compared to none in the placebo
group
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Multiple studies are being conducted to
establish the efficacy and safety of combining
basal insulin to GLP1R agonists, and these
combinations can provide additional glycemic
control by reducing both fasting plasma glucose
and, to a lesser extent, postprandial plasma
glucose excursions, in addition to promoting
weight loss and a low rate of hypoglycemia.
Table 6 gives a summarized comparison of
IDegLira and IGlarLixi.
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inadequately controlled with basal
insulin ± sulfonylurea and were
randomized on lixisenatide or
placebo (311)
24 Lixisenatide signiﬁcantly improved
HbA1C by -0.88% compared to
placebo (p\0.0001) and more
patients treated with lixisenatide
achieved HbA1C of\7%
compared to placebo (35.6% versus
5.2%; p\0.0001)
There was a trend in weight
decreases in patients treated with




similar in patients not receiving
sulfonylureas, but was more
frequent with lixisenatide versus
placebo (32.6 versus 28.3%)
PPG postprandial plasma glucose
Table 6 Comparison of IDegLira and IGlarLixi
IDegLira IGlarLixi
Components Combination of insulin degludec (basal insulin with
a half-life of 25 h and duration of action[42 h),
and liraglutide (GLP1RA analog with half-life of
13 h and OD dosing)
Combination of insulin glargine (basal insulin with a
half-life of 12.5 h and duration of action 24 h), and
lixisenatide (a short acting GLP1RA analog with a






Approved by European Medical Agency for the
European Market
Not yet approved
GLP1RA glucagon-like peptide 1 receptor agonist, IDegLira insulin degludec and liraglutide, IGlarLixi insulin glargine and
lixisenatide
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